[{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Korean Cancer Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Korean Cancer Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korean Cancer Study Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Korean Cancer Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Oncology Genito-Urinary Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Oncology Genito-Urinary Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spanish Oncology Genito-Urinary Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Oncology Genito-Urinary Group \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Queen Mary University of London \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Termination","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Chiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Chiron","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Chiron"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen Aps","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Venture \/ Sass & Larsen Aps","highestDevelopmentStatusID":"10","companyTruncated":"Oncology Venture \/ Sass & Larsen Aps"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, Davis \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Davis \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Georgetown University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Florida","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"University of Florida \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ontario Clinical Oncology Group","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Ontario Clinical Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ontario Clinical Oncology Group \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Ontario Clinical Oncology Group \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ontario Clinical Oncology Group","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Ontario Clinical Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ontario Clinical Oncology Group \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Ontario Clinical Oncology Group \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Virginia \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Auckland District Health Board","sponsor":"University of Auckland, New Zealand | IGENZ | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NEW ZEALAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Auckland District Health Board","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Auckland District Health Board \/ University of Auckland, New Zealand | IGENZ | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Auckland District Health Board \/ University of Auckland, New Zealand | IGENZ | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Noah Hahn, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Noah Hahn, M.D.","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Noah Hahn, M.D."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Manmeet Ahluwalia, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Manmeet Ahluwalia, MD","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Manmeet Ahluwalia, MD"}]
Find Clinical Drug Pipeline Developments & Deals for Dovitinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
